OCGN · Insider Trading
Ocugen, Inc. Common Stock
Every open-market purchase and sale reported by OCGN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-13 | Shankar Musunuri | Chief Executive Officer | Sell | −525,991 | −$499.69K |
| 2026-09-11 | Shankar Musunuri | Chief Executive Officer | Sell | −525,991 | −$589.11K |
| 2026-06-17 | Treerita Essalima Johnson-Greene | Chief Financial Officer | Buy | +21,000 | +$25.83K |
| 2026-06-15 | Kirsten Castillo | Director | A | +170,100 deriv. | — |
| 2026-06-15 | Satishchandran Chandrasekhar | Director | A | +170,100 deriv. | — |
| 2026-06-15 | Blaise Coleman | Director | A | +170,100 deriv. | — |
| 2026-06-15 | Junge Zhang | Director | A | +170,100 deriv. | — |
| 2026-06-15 | Uday Kompella | Director | A | +170,100 deriv. | — |
| 2026-04-02 | Junge Zhang | Director | M | +194,134 | +$154.30K |
| 2026-01-06 | Ramesh Ramachandran | Chief Accounting Officer | A | +207,300 | — |
| 2026-01-06 | Shankar Musunuri | Chief Executive Officer | A | +3,123,201 | — |
| 2025-06-09 | Kirsten Castillo | Director | A | +151,316 deriv. | — |
| 2025-06-09 | Uday Kompella | Director | A | +151,316 deriv. | — |
| 2025-06-09 | Junge Zhang | Director | A | +151,316 deriv. | — |
| 2025-06-09 | Satishchandran Chandrasekhar | Director | A | +151,316 deriv. | — |
| 2025-06-09 | Blaise Coleman | Director | A | +151,316 deriv. | — |
| 2025-01-06 | Huma Qamar | Chief Medical Officer | A | +1,145,468 deriv. | — |
| 2025-01-06 | Ramesh Ramachandran | Chief Accounting Officer | A | +350,146 deriv. | — |
| 2025-01-06 | Arun Upadhyay | See Remarks | F | −41,633 | −$37.24K |
| 2025-01-06 | Shankar Musunuri | Chief Executive Officer | F | −177,146 | −$158.46K |
| 2024-12-02 | Prabhavathi Fernandes | Director | Buy | +10,000 | +$9.10K |
| 2024-11-26 | Kirsten Castillo | Director | Buy | +25,000 | +$22.85K |
| 2024-09-26 | Arun Upadhyay | See Remarks | F | −842 | −$985 |
| 2024-07-02 | Junge Zhang | Director | A | +66,929 deriv. | — |
| 2024-07-02 | Arun Upadhyay | See Remarks | F | −917 | −$1.30K |
| 2024-07-02 | Marna C Whittington | Director | A | +66,929 deriv. | — |
| 2024-07-02 | Kirsten Castillo | Director | A | +66,929 deriv. | — |
| 2024-07-02 | Prabhavathi Fernandes | Director | A | +66,929 deriv. | — |
| 2024-07-02 | Uday Kompella | Director | A | +66,929 deriv. | — |
| 2024-04-17 | Huma Qamar | Chief Medical Officer | A | +308,465 deriv. | — |
| 2024-01-05 | Shankar Musunuri | Chief Executive Officer | F | −180,204 | −$117.67K |
| 2024-01-05 | Arun Upadhyay | See Remarks | F | −41,633 | −$27.19K |
| 2024-01-04 | Arun Upadhyay | See Remarks | A | +137,795 deriv. | — |
| 2024-01-04 | Shankar Musunuri | Chief Executive Officer | A | +492,126 deriv. | — |
| 2023-09-19 | Arun Upadhyay | See Remarks | F | −842 | −$345 |
| 2023-06-20 | Arun Upadhyay | Chief Scientific Officer | F | −917 | −$468 |
| 2023-06-16 | Junge Zhang | Director | Buy | +200,278 | +$100.00K |
| 2023-06-09 | Kirsten Castillo | Director | A | +112,205 deriv. | — |
| 2023-06-09 | Junge Zhang | Director | A | +112,205 deriv. | — |
| 2023-06-09 | Marna C Whittington | Director | A | +112,205 deriv. | — |
| 2023-06-09 | Uday Kompella | Director | A | +112,205 deriv. | — |
| 2023-06-09 | Prabhavathi Fernandes | Director | A | +112,205 deriv. | — |
| 2023-06-09 | Ramesh Kumar | Director | A | +112,205 deriv. | — |
| 2023-02-17 | Jessica Crespo | CAO/SVP, Finance | F | −1,913 | −$2.39K |
| 2023-02-17 | Shankar Musunuri | Chief Executive Officer | MIXED | −37,877 | −$122.35K |
| 2023-02-17 | Arun Upadhyay | Chief Scientific Officer | F | −7,102 | −$8.88K |
| 2023-01-19 | Shankar Musunuri | Chief Executive Officer | MIXED | — | −$77.00K |
| 2023-01-05 | Jessica Crespo | CAO/SVP, Finance | A | +122,951 | — |
| 2023-01-05 | Shankar Musunuri | Chief Executive Officer | A | +1,475,410 | — |
| 2023-01-05 | Arun Upadhyay | Chief Scientific Officer | A | +315,924 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Shankar Musunuri | Chief Executive Officer | 5,049,241 | $4.09M |
| Junge Zhang | Director | 2,436,498 | $1.97M |
| Uday Kompella | Director | 705,090 | $571.44K |
| Treerita Essalima Johnson-Greene | Chief Financial Officer | 521,350 | $422.53K |
| Arun Upadhyay | See Remarks | 306,197 | $248.16K |
| Ramesh Ramachandran | Chief Accounting Officer | 209,100 | $169.47K |
| Kirsten Castillo | Director | 75,000 | $60.78K |
| Prabhavathi Fernandes | Director | 10,000 | $8.10K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OCGN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.